Aviso Financial Inc. Reduces Stock Position in GSK plc (NYSE:GSK)

Aviso Financial Inc. trimmed its holdings in GSK plc (NYSE:GSK) by 8.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,753 shares of the pharmaceutical company’s stock after selling 759 shares during the period. Aviso Financial Inc.’s holdings in GSK were worth $262,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Indiana Trust & Investment Management Co boosted its holdings in GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 500 shares during the period. Crews Bank & Trust bought a new position in shares of GSK in the 4th quarter worth about $26,000. ST Germain D J Co. Inc. boosted its holdings in shares of GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after buying an additional 522 shares during the period. Sunbelt Securities Inc. grew its position in shares of GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares during the last quarter. Finally, Sierra Ocean LLC acquired a new stake in GSK during the fourth quarter worth about $32,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GSK has been the subject of several recent research reports. Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating for the company. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research note on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to data from MarketBeat.com, GSK currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Trading Up 0.8 %

Shares of GSK stock opened at $39.54 on Friday. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.93. The firm has a market capitalization of $81.94 billion, a PE ratio of 24.86, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The stock has a fifty day moving average of $36.05 and a two-hundred day moving average of $37.11. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, research analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.98%. The ex-dividend date of this dividend is Friday, February 21st. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is currently 98.74%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.